ReviewMolecular biology reports2020
Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion.
Review in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction: a Multicenter Randomized Double-blind Placebo-controlled Trial (OPTIMA-6)
Study on the Thrombolytic Effect of Platelet Membrane Coated Recombinant Staphylokinase on Human Arterial Thrombus
Who cites it
11 citing papers in PubMed, 40 citations in OpenAlex.
- Rapid screening of staphylokinase protein variants using an unpurified cell-free expression system.FEBS open bio · 2026Article
- Cardiac magnetic resonance assessment of long-term cardiac function after early recombinant staphylokinase thrombolysis before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction patients.Quantitative imaging in medicine and surgery · 2026Article
- Rather a versatile multi-tool than a sword: an integral role of the plasminogen system in health and disease.Frontiers in immunology · 2026Review
- Review
- Application of microbial enzymes in medicine and industry: current status and future perspectives.Future microbiology · 2024Review
- Case Report: First attempt by off-label use of tenecteplase to treat acute extensive portal venous system thrombosis.Frontiers in cardiovascular medicine · 2024Article
- CcpA RegulatesAntibiotics (Basel, Switzerland) · 2022Article
- Computer-aided engineering of staphylokinase toward enhanced affinity and selectivity for plasmin.Computational and structural biotechnology journal · 2022Article
- Recombinant Destabilase fromCurrent issues in molecular biology · 2021Article
- Thrombolytic Enzymes of Microbial Origin: A Review.International journal of molecular sciences · 2021Review
- Role of Fibrinolytic Enzymes in Anti-Thrombosis Therapy.Frontiers in molecular biosciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular occlusion is one of the major causes of mortality and morbidity. Blood vessel blockage can lead to thrombotic complications such as myocardial infarction, stroke, deep venous thrombosis, peripheral occlusive disease, and pulmonary embolism. Thrombolytic therapy currently aims to rectify this through the administration of recombinant tissue plasminogen activator. Research is underway to design an ideal thrombolytic drug with the lowest risk. Despite the potent clot lysis achievable using approved thrombolytic drugs such as alteplase, reteplase, streptokinase, tenecteplase, and some other fibrinolytic agents, there are some drawbacks, such as high production cost, systemic bleeding, intracranial hemorrhage, vessel re-occlusion by platelet-rich and retracted secondary clots, and non-fibrin specificity. In comparison, bacterial staphylokinase, is a new, small-size plasminogen activator, unlike bacterial streptokinase, it hinders the systemic degradation of fibrinogen and reduces the risk of severe hemorrhage. A fibrin-bound plasmin-staphylokinase complex shows high resistance to a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.